首页|非奈利酮用于糖尿病肾病药学实践并文献分析

非奈利酮用于糖尿病肾病药学实践并文献分析

扫码查看
目的 促进非奈利酮在糖尿病肾病患者中的合理使用.方法 针对深圳市罗湖区人民医院收治的 1 例糖尿病肾病患者的大量白蛋白尿症状,药师会诊中检索国内外关于非奈利酮的文献报道,协助医师制订及调整药物治疗方案,并于患者入院第 4 天根据具体情况建议加用非奈利酮(10 mg,每日 1 次,口服).结果 医师采纳临床药师用药建议,患者的大量白蛋白尿及低血钾等其他症状得到有效改善.入院第 10 天,患者血糖控制尚可,乏力及下肢水肿较前好转,后出院.结论 临床药师通过分析病情及查阅文献参与药学监护,可确保糖尿病肾病患者药物治疗的有效性和安全性,也有助于非奈利酮在该病中的正确、合理使用.
Pharmaceutical Practice and Literature Analysis of Finerenone for Diabetic Nephropathy
Objective To promote the rational use of finerenone in patients with diabetic nephropathy.Methods For the massive proteinuria in a patient with diabetic nephropathy admitted to Luohu People´s Hospital,the pharmacists assisted physicians to formulate and adjust the treatment regimens based on the domestic and foreign literature on finerenone,and suggested the addition of finerenone(10 mg,once a day,oral)according to the patient´s disease condition on the fourth day of admission.Results The physicians adopted the medication suggestions of the clinical pharmacists,and the patient´s conditions such as massive proteinuria and hypokalemia effectively improved.On the 10th day of admission,the patient´s blood glucose was well controlled,his weakness and lower limb edema improved,and then he successfully discharged from the hospital.Conclusion Clinical pharmacists´ participation in the pharmaceutical care based on disease analysis and literature review can ensure the effectiveness and safety of drug treatment for patients with diabetic nephropathy,and also promote the correct and rational use of finerenone in the treatment of this disease.

finerenonediabetic nephropathyproteinuriaheart and kidney outcomesblood potassium

曹馨月、曹伟灵、朱丹华、郑桂梅

展开 >

深圳大学附属华南医院,广东 深圳 518111

广东省深圳市罗湖区人民医院,广东 深圳 518000

非奈利酮 糖尿病肾病 白蛋白尿 心肾结局 血钾

广东省医院协会药学科研专项基金广东省深圳市罗湖区人民医院临床研究项目

2022YSGL04LCYJ202203

2024

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
年,卷(期):2024.33(18)
  • 1